TGTX (STOCKS)
TG Therapeutics, Inc.
$47.940000
-1.560000 (-3.15%)
Prev close: $49.500000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Michael Sean Weiss
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $7,870.67M
- Employees
- 352
- P/E (TTM)
- 18.03
- P/B (TTM)
- 12.54
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
9
Buy
1
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$0.05 | $0.34 | -0.2943 | -85.48% |
|
Mar 2026 (Q1)
|
$0.18 | $0.30 | -0.1205 | -40.10% |
|
Dec 2025 (Q4)
|
$0.14 | $0.36 | -0.2183 | -60.93% |
|
Sep 2025 (Q3)
|
$0.16 | $0.22 | -0.0644 | -28.70% |
Financial Statements
| Revenues | $799.54M |
| Benefits Costs and Expenses | $697.94M |
| Cost Of Revenue | $140.94M |
| Costs And Expenses | $663.21M |
| Gross Profit | $658.60M |
| Nonoperating Income/Loss | -$34.73M |
| Operating Expenses | $522.27M |
| Selling, General, and Administrative Expenses | $296.47M |
| Research and Development | $225.80M |
| Operating Income/Loss | $136.33M |
| Income/Loss From Continuing Operations After Tax | $441.49M |
| Income/Loss From Continuing Operations Before Tax | $101.60M |
| Income Tax Expense/Benefit | -$339.89M |
| Income Tax Expense/Benefit, Deferred | -$343.43M |
| Net Income/Loss | $441.49M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $441.49M |
| Net Income/Loss Available To Common Stockholders, Basic | $441.49M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $3.08 |
| Diluted Earnings Per Share | $2.75 |
| Basic Average Shares | 429,669,786 |
| Diluted Average Shares | 477,652,526 |
| Assets | $1.64B |
| Current Assets | $1.15B |
| Cash | $612.30M |
| Inventory | $147.97M |
| Other Current Assets | $385.41M |
| Noncurrent Assets | $493.94M |
| Liabilities | $1.04B |
| Current Liabilities | $268.49M |
| Noncurrent Liabilities | $767.05M |
| Equity | $604.08M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $604.08M |
| Liabilities And Equity | $1.64B |
| Net Cash Flow From Operating Activities | $17.88M |
| Net Cash Flow From Operating Activities, Continuing | $17.88M |
| Net Cash Flow From Investing Activities | $21.89M |
| Net Cash Flow From Investing Activities, Continuing | $21.89M |
| Net Cash Flow From Financing Activities | $313.73M |
| Net Cash Flow From Financing Activities, Continuing | $313.73M |
| Net Cash Flow | $353.50M |
| Net Cash Flow, Continuing | $353.50M |
| Comprehensive Income/Loss | $441.49M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $441.49M |
| Other Comprehensive Income/Loss | $0.00 |